Matthew D. Shirley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Matthew D. Shirley has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
David A. Ruddy
32 shared publicationsAli Farsidjani
26 shared publicationsPeter S. Hammerman
24 shared publicationsBhavesh Pant
19 shared publicationsCharles F. Voliva
19 shared publicationsChen Liu
19 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma
Supplementary Figure S1 shows additional shRNA knockdown data in uveal melanoma cell lines. Supplementary Figure S2 shows additional dual BRG1/BRM knockdown data and BRG1 rescue data. Supplementary Figure S3 shows basal SWI/SNF subunit expression, additional caspase activity and viability data in compound treated and shRNA knockdown cell lines, and SWI/SNF mutations in uveal melanoma cells lines. Supplementary Figure S4 shows additional MITF knockdown data and further RNA-Seq and ATAC-Seq data set analyses. Supplementary Figure S5 shows target gene modulation by compound treatment in uveal melanoma cell lines and additional MITF overexpression rescue data. Supplementary Figure S6 shows genomic location of primers used in ChIP-qPCR experiment.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma
Supplementary Figure S1 shows additional shRNA knockdown data in uveal melanoma cell lines. Supplementary Figure S2 shows additional dual BRG1/BRM knockdown data and BRG1 rescue data. Supplementary Figure S3 shows basal SWI/SNF subunit expression, additional caspase activity and viability data in compound treated and shRNA knockdown cell lines, and SWI/SNF mutations in uveal melanoma cells lines. Supplementary Figure S4 shows additional MITF knockdown data and further RNA-Seq and ATAC-Seq data set analyses. Supplementary Figure S5 shows target gene modulation by compound treatment in uveal melanoma cell lines and additional MITF overexpression rescue data. Supplementary Figure S6 shows genomic location of primers used in ChIP-qPCR experiment.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma
Supplementary Figure S1 shows additional shRNA knockdown data in uveal melanoma cell lines. Supplementary Figure S2 shows additional dual BRG1/BRM knockdown data and BRG1 rescue data. Supplementary Figure S3 shows basal SWI/SNF subunit expression, additional caspase activity and viability data in compound treated and shRNA knockdown cell lines, and SWI/SNF mutations in uveal melanoma cells lines. Supplementary Figure S4 shows additional MITF knockdown data and further RNA-Seq and ATAC-Seq data set analyses. Supplementary Figure S5 shows target gene modulation by compound treatment in uveal melanoma cell lines and additional MITF overexpression rescue data. Supplementary Figure S6 shows genomic location of primers used in ChIP-qPCR experiment.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma
Supplementary Figure S1 shows additional shRNA knockdown data in uveal melanoma cell lines. Supplementary Figure S2 shows additional dual BRG1/BRM knockdown data and BRG1 rescue data. Supplementary Figure S3 shows basal SWI/SNF subunit expression, additional caspase activity and viability data in compound treated and shRNA knockdown cell lines, and SWI/SNF mutations in uveal melanoma cells lines. Supplementary Figure S4 shows additional MITF knockdown data and further RNA-Seq and ATAC-Seq data set analyses. Supplementary Figure S5 shows target gene modulation by compound treatment in uveal melanoma cell lines and additional MITF overexpression rescue data. Supplementary Figure S6 shows genomic location of primers used in ChIP-qPCR experiment.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma
Supplementary Table S1 lists biochemical and cellular activity of BRG1/BRM inhibitors. Supplementary Table S2 lists BRM011 and BRM014 activity across cell line panel. Supplementary Table S3 lists cell lines generated for this study. Supplementary Table S4 lists antibody and qPCR probes used in this study.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma
Supplementary Table S1 lists biochemical and cellular activity of BRG1/BRM inhibitors. Supplementary Table S2 lists BRM011 and BRM014 activity across cell line panel. Supplementary Table S3 lists cell lines generated for this study. Supplementary Table S4 lists antibody and qPCR probes used in this study.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Supplementary Table 2: List of all cell lines in the CCLE where sensitivity to SHP099 was evaluated in 2D. Lineage and genetic status of KRAS and BRAF are shown. Blank cells represent cell line data where genetic or screening data do not exist. Data depicted in Figure 1B are IC50 values. This table includes all sensitivity data based on both IC50 and Amax data.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Supplementary Table 2: List of all cell lines in the CCLE where sensitivity to SHP099 was evaluated in 2D. Lineage and genetic status of KRAS and BRAF are shown. Blank cells represent cell line data where genetic or screening data do not exist. Data depicted in Figure 1B are IC50 values. This table includes all sensitivity data based on both IC50 and Amax data.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-3 from RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation
Supplementary Table S1 contains contingency tables used for Fisher's Exact Test to determine enrichment of binary features in genetic dependency profiles for BRAF, MAPK1 (ERK2), and MAPK3 (ERK1) by BRAFV600 mutation status from three independent screens: DRIVE, ACHILLES, and AVANA. Supplementary Table S2 contains genetic dependency scores for BRAF, MAPK1 (ERK2), and MAPK3 (ERK1) in all BRAF-mutant melanoma cell lines included in three independent screens: DRIVE, ACHILLES, and AVANA. Supplementary Table S3 contains gene set enrichment analysis of RNAseq data from A375 cells with ERK1 or ERK2 knockdown.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-3 from RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation
Supplementary Table S1 contains contingency tables used for Fisher's Exact Test to determine enrichment of binary features in genetic dependency profiles for BRAF, MAPK1 (ERK2), and MAPK3 (ERK1) by BRAFV600 mutation status from three independent screens: DRIVE, ACHILLES, and AVANA. Supplementary Table S2 contains genetic dependency scores for BRAF, MAPK1 (ERK2), and MAPK3 (ERK1) in all BRAF-mutant melanoma cell lines included in three independent screens: DRIVE, ACHILLES, and AVANA. Supplementary Table S3 contains gene set enrichment analysis of RNAseq data from A375 cells with ERK1 or ERK2 knockdown.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Supplementary Table 1: List of all cell lines in the CCLE (Cancer Cell Line Encyclopedia) where sensitivity to SHP2 (PTPN11) knockdown was evaluated in 2D. Lineage, and genetic status of KRAS and BRAF are shown. Blank cells represent cell line data where genetic or sensitivity data do not exist. Values depicted are the ATARIS quantile normalized z-score. Additional details on the methodology of the screen are published (58).
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Supplementary Table 1: List of all cell lines in the CCLE (Cancer Cell Line Encyclopedia) where sensitivity to SHP2 (PTPN11) knockdown was evaluated in 2D. Lineage, and genetic status of KRAS and BRAF are shown. Blank cells represent cell line data where genetic or sensitivity data do not exist. Values depicted are the ATARIS quantile normalized z-score. Additional details on the methodology of the screen are published (58).
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Supplementary Material and Methods. File contains the following: Transcriptome sequencing and analysis, Soft agar assay, 2D and 3D Cell proliferation screen and compound characterization information.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Supplementary Material and Methods. File contains the following: Transcriptome sequencing and analysis, Soft agar assay, 2D and 3D Cell proliferation screen and compound characterization information.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma
Additional method details for ATAC-Seq Data Analysis and ChIP-qPCR
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma
Additional method details for ATAC-Seq Data Analysis and ChIP-qPCR
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
In vivo efficacy of SHP099 (100 mg/kg, daily) in the KYSE-520 esophageal cancer cell line model. Data are plotted as the treatment mean {plus minus} s.e.m (n=7) ( (B-I) In vivo efficacy data for cell line models represented in Fig. 3E. SHP099 and trametinib were orally administered at the doses, schedules and for the duration indicated. Data are plotted as the treatment mean {plus minus} s.e.m.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
In vivo efficacy of SHP099 (100 mg/kg, daily) in the KYSE-520 esophageal cancer cell line model. Data are plotted as the treatment mean {plus minus} s.e.m (n=7) ( (B-I) In vivo efficacy data for cell line models represented in Fig. 3E. SHP099 and trametinib were orally administered at the doses, schedules and for the duration indicated. Data are plotted as the treatment mean {plus minus} s.e.m.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
(A) Immunoblot of p-RSK3 and qPCR for DUSP6 from MIA PaCa-2 xenografts collected 3 hours after the last dose from Fig 5C. (B) Immunoblot for the designated proteins from MIA PaCa-2 cells grown in 2D, 3D and from in vivo xenografts without compound treatment. Protein loading amount was normalized and verified by tubulin loading control. Each separate column represents an individual treated tumor. (C) Dependency of MET by DRIVE pooled shRNA screen (y axis, ATARIS Quantile score of less than -0.5 indicates a significant effect) and expression of HGF (x-axis) by RNAseq in pancreatic cancer cell lines in CCLE (n=21). (D) Immunoblot of p-RSK3 and qPCR for DUSP6 from KP4 xenografts collected 3 hours after the last dose from Fig 5E. Protein loading amount was normalized and verified by tubulin loading control. Each separate column represents an individual treated tumor (E) Immunoblot for the designated proteins from KP4 cells grown in 2D, 3D and from in vivo xenografts without compound treatment (F) Schematic of RTK-SHP2 signaling highlighting that SHP2 acts downstream of one or more activated RTKs to elicit downstream signaling in KRAS mutant and also additional SHP2-specific, non-MAPK signaling. SHP2 inhibition by SHP099 can serve as a surrogate for cancers where KRAS mutant cancers are dependent on upstream RTKs.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
(A) Immunoblot of p-RSK3 and qPCR for DUSP6 from MIA PaCa-2 xenografts collected 3 hours after the last dose from Fig 5C. (B) Immunoblot for the designated proteins from MIA PaCa-2 cells grown in 2D, 3D and from in vivo xenografts without compound treatment. Protein loading amount was normalized and verified by tubulin loading control. Each separate column represents an individual treated tumor. (C) Dependency of MET by DRIVE pooled shRNA screen (y axis, ATARIS Quantile score of less than -0.5 indicates a significant effect) and expression of HGF (x-axis) by RNAseq in pancreatic cancer cell lines in CCLE (n=21). (D) Immunoblot of p-RSK3 and qPCR for DUSP6 from KP4 xenografts collected 3 hours after the last dose from Fig 5E. Protein loading amount was normalized and verified by tubulin loading control. Each separate column represents an individual treated tumor (E) Immunoblot for the designated proteins from KP4 cells grown in 2D, 3D and from in vivo xenografts without compound treatment (F) Schematic of RTK-SHP2 signaling highlighting that SHP2 acts downstream of one or more activated RTKs to elicit downstream signaling in KRAS mutant and also additional SHP2-specific, non-MAPK signaling. SHP2 inhibition by SHP099 can serve as a surrogate for cancers where KRAS mutant cancers are dependent on upstream RTKs.